K2m Group Holdings, Inc. (KTWO): Carlos A Ferrer , director of K2m Group Holdings, Inc. purchased 20,000 shares on May 5, 2016. The Insider buying transaction was reported by the company on May 5, 2016 to the Securities and Exchange Commission. The shares were purchased at $11.32 per share for a total value of $226,400.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 7, 2016, Carlos A Ferrer (director) purchased 38,942 shares at $12.84 per share price.On Nov 13, 2015, Gregory S Cole (Chief Financial Officer) sold 41,574 shares at $19.69 per share price.Also, On Jun 24, 2015, John Philip Md Kostuik (Chief Medical Officer) sold 24,337 shares at $24.84 per share price.On Feb 13, 2015, Brett Brodnax (director) sold 5,564 shares at $19.73 per share price.
Shares of K2M Group Holdings Inc (KTWO) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -0.88 points or -7.71% at $10.54 with 9,06,125 shares getting traded. Post opening the session at $11.26, the shares hit an intraday low of $10.51 and an intraday high of $11.6 and the price vacillated in this range throughout the day. The company has a market cap of $436 M and the number of outstanding shares has been calculated to be 4,13,37,692 shares. The 52-week high of K2M Group Holdings Inc is $26.29 and the 52-week low is $10.51.
Company has been under the radar of several Street Analysts.K2M Group Holdings Inc is Downgraded by Northland Capital to Market Perform. Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on May 3, 2016.K2M Group Holdings Inc is Initiated by JMP Securities to Mkt Outperform. The Rating was issued on Apr 8, 2016.K2M Group Holdings Inc is Reiterated by Needham to Buy while Lowering the Price Target of the company shares to $ 21 from a previous price target of $25 . The Rating was issued on Mar 4, 2016.
K2M Group Holdings Inc. (KTWO) is a global medical device company focused on designing developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies such as deformity (primarily scoliosis) trauma and tumor. The Company is engaged in the design development and commercialization of a number of minimally invasive spine (MIS) products and products for patients suffering from degenerative spinal conditions. The Company’s products consist of implants disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s technologies include MESA Rail 4D Deformity Cricket CAPRI SERENGETI RAVINE EVEREST and tifix. The Company offers products-based on its technologies for complex spine minimally invasive spine and degenerative spine. The Company is engaged in product development activities for the spine and MIS markets.